Durect Corp DRRX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if DRRX is a good fit for your portfolio.
News
-
DURECT Corporation Reports Third Quarter 2023 Financial Results and Business Update
-
DURECT Corporation to Announce Third Quarter 2023 Financial Results and Provide a Business Update
-
DURECT Corporation Announces Topline Results from Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis with Promising Effect on Mortality
-
DURECT Corporation Announces Last Patient Last Visit in Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis
Trading Information
- Previous Close Price
- $0.66
- Day Range
- $0.64–0.69
- 52-Week Range
- $0.47–7.46
- Bid/Ask
- $0.64 / $0.69
- Market Cap
- $19.72 Mil
- Volume/Avg
- 502,240 / 746,821
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 1.78
- Dividend Yield
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Durect Corp is a biopharmaceutical company. It is engaged in the research, development, and manufacturing of pharmaceutical products. The company develops pharmaceutical products based on two categories which include new chemical entities and proprietary pharmaceutical programs. The company's pipeline products consist of DUR-928, POSIMIR, and others. Geographically, the company operates in the United States, Europe, Japan, and other countries, of which key revenue is derived from the Europe .
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Value
- Total Number of Employees
- 79
- Website
- https://www.durect.com
Valuation
|
Metric
|
DRRX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.31 |
Price/Sales | 1.78 |
Price/Cash Flow | — |
Price/Earnings
DRRX
Financial Strength
|
Metric
|
DRRX
|
|---|---|
Quick Ratio | 1.08 |
Current Ratio | 1.19 |
Interest Coverage | −13.14 |
Quick Ratio
DRRX
Profitability
|
Metric
|
DRRX
|
|---|---|
Return on Assets (Normalized) | −58.62% |
Return on Equity (Normalized) | −178.96% |
Return on Invested Capital (Normalized) | −81.97% |
Return on Assets
DRRX
Drug Manufacturers - Specialty & Generic Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|
ZTS
| Zoetis Inc Class A | Ycbt | $83.6 Bil | |
MKKGY
| Merck KGaA ADR | Nkfvys | $67.1 Bil | |
HLN
| Haleon PLC ADR | Vhwq | $37.9 Bil | |
VTRS
| Viatris Inc | Wmyx | $11.6 Bil | |
RDY
| Dr Reddy's Laboratories Ltd ADR | Znlr | $11.4 Bil | |
TEVA
| Teva Pharmaceutical Industries Ltd ADR | Dpjk | $11.3 Bil | |
CTLT
| Catalent Inc | Sljqg | $6.8 Bil | |
PRGO
| Perrigo Co PLC | Vfcg | $4.0 Bil | |
EVO
| Evotec SE ADR | Fxnm | $3.7 Bil | |
CURLF
| Curaleaf Holdings Inc | Zrgt | $3.2 Bil |